Abstracts tagged "Disease Activity and interleukins (IL)"

Abstract Number: 1509 • ACR/ARP Annual Meeting 2019

Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies

Atul Deodhar¹, Philip Mease ², Paula Machado ³, Xiangyi Meng ³, Vibeke Strand ⁴ and Marina Magrey ⁵, ¹Oregon Health & Science University, Portland, OR, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁵Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH